Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
09 Octubre 2024 - 6:00AM
Business Wire
Conference Call and Webcast Scheduled for 1:30
p.m. PT
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical
and medical technology company focused on novel therapies for the
treatment of glaucoma, corneal disorders and retinal diseases,
plans to release third quarter 2024 financial results after the
market close on Monday, November 4, 2024. The company’s management
will discuss the results during a conference call and simultaneous
webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 4, 2024.
A link to the live webcast will be available on the company’s
website at http://investors.glaukos.com. To participate in the
conference call, please dial 888-210-2212 (U.S.) or 646-960-0390
(International) and enter Conference ID 7935742. A replay will be
archived on the company’s website following completion of the
call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and
medical technology company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012. In 2024, Glaukos commenced commercial
launch activities for iDose® TR, a first-of-its-kind,
long-duration, intracameral procedural pharmaceutical designed to
deliver 24/7 glaucoma drug therapy inside the eye for extended
periods of time. Glaukos also markets the only FDA-approved corneal
cross-linking therapy utilizing a proprietary bio-activated
pharmaceutical for the treatment of keratoconus, a rare corneal
disorder. Glaukos continues to successfully develop and advance a
robust pipeline of novel, dropless platform technologies designed
to meaningfully advance the standard of care and improve outcomes
for patients suffering from chronic eye diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241009112791/en/
Chris Lewis Vice President, Investor Relations and Corporate
Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
